ARCUTIS BIOTHERAPEUTICS, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 3.98 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-05
- ARCUTIS BIOTHERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-06-30 was 3.98M shares, a 70.58% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 13.79M shares, a 3.10% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 13.53M shares.
- ARCUTIS BIOTHERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 14.23M shares, a 12.55% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 12.46M shares, a 9.13% increase from fiscal 2024.
- ARCUTIS BIOTHERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 11.41M shares, a 4.95% increase from fiscal 2023.
- ARCUTIS BIOTHERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 10.88M shares, a 19.71% increase from fiscal 2022.
- ARCUTIS BIOTHERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 9.08M shares, a 46.63% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | 3.98M shares 10-Q · filed 2026-08-05 | 3.66M shares 10-Q · filed 2026-08-05 | ||
| 2026-03-31 | 13.79M shares 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | 12.46M shares 10-K · filed 2026-02-25 | |||
| 2025-09-30 | 2.78M shares 10-Q · filed 2025-10-28 | |||
| 2025-06-30 | 13.53M shares 10-Q · filed 2026-08-05 | 13.53M shares 10-Q · filed 2026-08-05 | ||
| 2025-03-31 | 14.23M shares 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | 11.41M shares 10-K · filed 2026-02-25 | |||
| 2024-09-30 | 12.24M shares 10-Q · filed 2025-10-28 | |||
| 2024-06-30 | 12.58M shares 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | 12.65M shares 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | 10.88M shares 10-K · filed 2026-02-25 | |||
| 2023-09-30 | 11.23M shares 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | 11.19M shares 10-Q · filed 2024-08-14 | |||
| 2023-03-31 | 11.26M shares 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | 9.08M shares 10-K · filed 2025-02-25 | |||
| 2022-09-30 | 9.12M shares 10-Q · filed 2023-11-03 | |||
| 2022-06-30 | 8.74M shares 10-Q · filed 2023-08-08 | |||
| 2022-03-31 | 8.27M shares 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | 6.20M shares 10-K · filed 2024-02-27 | |||
| 2021-09-30 | 6.21M shares 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | 5.58M shares 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | 5.11M shares 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | 4.16M shares 10-K · filed 2023-02-28 | |||
| 2020-09-30 | 4.20M shares 10-Q · filed 2021-11-04 | |||
| 2020-06-30 | 3.88M shares 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | 3.89M shares 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | 27.66M shares 10-K · filed 2022-02-22 | |||
| 2019-09-30 | 18.72M shares 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | 18.91M shares 10-Q · filed 2020-08-11 | |||
| 2019-03-31 | 18.65M shares 10-Q · filed 2020-05-12 | |||
| 2018-12-31 | 17.71M shares 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |